title: [Home intravenous antibiotic treatments in cystic fibrosis units of Madrid].
abstract: OBJECTIVE
  A descriptive study of the home intravenous antibiotic treatment (HIVAT) course in cystic fibrosis (CF) units of Madrid in an 18 month period. Different patient features were recorded, antibiotherapy, intravenous access, complications and their resolutions. We accessed the improvement of the pulmonary function, forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) at the end of the treatment.
  
  
  METHODS
  For an 18 months period (January 2002-June 2003) the patients with CF who received HIVAT and fulfilled the previously fixed criteria were included. The next clinic variables were collected: age, sex, bacterial colonization of respiratory tree, pancreatic function and pulmonary function in steady phase, before and after HIAT.
  
  
  RESULTS
  56 patients, 31 male and 25 female, were given 90 courses of HIAT (34 patients received only one course). Mean age was 20.06 (8.07) years. 57.1% of the patients were colonized by Pseudomonas aeruginosa. The most frequently used antibiotics were ceftazidime and tobramycin. Courses of treatment lasted a mean of 4.08 (5.09) days inpatient and 11.89 (4.96) at home. In 87.7% of the course were used the intravenous cannulae, Port-a-cath in 6.7% and Venocath in 7.8%. The intravenous access was replaced, in the 64.4% of the cases, by the nurse of the CF Unit, in the 21.4% in the emergency room of the nearest hospital and in 11.9% in primary care center. Three occasions skin reactions were reported. The parameters of pulmonary function improved significatively after HIVAT.
  
  
  CONCLUSIONS
  The HIVAT is a therapeutic option that, following predetermined inclusion criteria, has a low complication rate and improves pulmonary function.
authors.affiliation: Servicio de la Neumologia, Hospital Universitario de La Princesa, Diego de León 62, 28006 Madrid, Spain.
authors.forename: Rosa María
authors.initials: RM
authors.lastname: Girón
authors.forename: Ana
authors.initials: A
authors.lastname: Martínez
authors.forename: Luís
authors.initials: L
authors.lastname: Máiz
authors.forename: Antonio
authors.initials: A
authors.lastname: Salcedo
authors.forename: Blanca
authors.initials: B
authors.lastname: Beltrán
authors.forename: María Teresa
authors.initials: MT
authors.lastname: Martínez
authors.forename: Carmen
authors.initials: C
authors.lastname: Antelo
authors.forename: Isabel
authors.initials: I
authors.lastname: Barrio
authors.forename: Concha
authors.initials: C
authors.lastname: Prados
authors.forename: Juan
authors.initials: J
authors.lastname: Cabanillas
authors.forename: Julio
authors.initials: J
authors.lastname: Ancochea
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002442:Ceftazidime / Q000008:administration & dosage; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy*; D005260:Female; D018718:Home Infusion Therapy / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D008297:Male; D012129:Respiratory Function Tests; D013030:Spain; D014031:Tobramycin / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D002442:Ceftazidime; D014031:Tobramycin